Gong et al. (2017) reported that NF-κβ was highly expressed in OSA, which is important for the early diagnosis and prognosis of OSA. EA is a potent NF-κβ inhibitor and induces apoptosis through NF-κβ inhibition (Shakeri et al. 2018). In parallel with these findings, EA, in combination doses, increased the inhibition of the expression of NF-κβ in the current study. This evidence concerns the gene NFKB1 and obstructive sleep apnea syndrome.